scispace - formally typeset
M

Mckenna Longacre

Researcher at Brigham and Women's Hospital

Publications -  16
Citations -  2763

Mckenna Longacre is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Cancer & DNA methylation. The author has an hindex of 8, co-authored 16 publications receiving 2116 citations. Previous affiliations of Mckenna Longacre include Washington University in St. Louis & Harvard University.

Papers
More filters
Journal ArticleDOI

Drug Resistance in Cancer: An Overview

TL;DR: The current knowledge of mechanisms that promote or enable drug resistance, such as drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, and the epithelial-mesenchymal transition, as well as how inherent tumor cell heterogeneity plays a role in drug resistance are outlined.
Journal ArticleDOI

EMT and tumor metastasis.

TL;DR: It is hypothesized that reversible epigenetic events regulate both EMT and MET, and thus, also regulate the development of different types of metastatic cancers.
Journal ArticleDOI

Cancer Development, Progression, and Therapy: An Epigenetic Overview

TL;DR: It is proposed that predisposed normal cells convert to cancer progenitor cells that, after growing, undergo an epithelial-mesenchymal transition, which can create a metastatic form of both progenitors and full-fledged cancer cells, after which metastasis to a distant location may occur.
Journal ArticleDOI

A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis.

TL;DR: Comparisons of genetic, microenvironmental, stromal, and epigenetic changes common between breast and ovarian cancer cells suggest shared features of pathogenesis, and preliminary evidence suggests a shared epigenetic mechanism of oncogenesis.
Journal Article

Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor.

TL;DR: Results showed that the combination of HDACi and calpeptin inhibited the growth of two distinctly different types of breast cancer cells and could have wide clinical applications, though the mechanisms of inhibition are possibly different.